Pro Medicus Limited (ASX:PME) is a Melbourne-based software owner and developer, licensing products to large US hospitals and Australian radiology clinics. The company has offices in Richmond, Victoria, Berlin, Germany and in the United States.
Reporting season is over. There were some big numbers. Some results got a positive reaction from investors. This article is about 5 of them.
Drew Meredith and Owen Rask are back for ASX Reporting Season covering Boral Ltd (ASX:BLD), Kogan.com Ltd (ASX: KGN), Coles Group Ltd (ASX:COL) and Altium Ltd (ASX:ALU).
The Pro Medicus Ltd (ASX:PME) share price is down after the company reported strong growth in FY22 and a good outlook for FY23.
The Volpara Health Technologies (ASX: VHT) share price jumped 6% today after the company released two important updates to the market: its quarterly cash flow report, and findings from CEO Teri Thomas’ strategic review.
The Pro Medicus Limited (ASX:PME) share price is down in 2022 while the S&P/ASX 200 (INDEXASX:XJO) is 7% down. The PME share price has been on a tear in recent years but PME shares are still not cheap.
So far in 2022 the Pro Medicus Limited (ASX: PME) share price has traced 32% lower. In that time, the Australian Ethical Investment Ltd (ASX: AEF) share price has drifted 63% lower. Ouch!
Today, the Volpara Health Technologies Ltd (ASX: VHT) share price leapt 21% higher after announcing it secured a roll-out of Volpara Risk Pathways and Volpara Analytics to the 350+ sites owned or operated by Radnet Inc (NASDAQ: RDNT).
Amongst the 100 best performing US stocks (i.e. those with 1000% returns or more) are Tesla Inc (NASDAQ: TSLA), NVIDIA (NASDAQ: NVDA) and Netflix Inc (NASDAQ: NFLX). Here are my lessons learned.
The Pro Medicus Ltd (ASX: PME) share price has been falling these past few months despite announcing some big wins. Indeed, investors are asking, is the PME share price is a buy?
